Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cogstate Ltd ( (AU:CGS) ).
Cogstate Limited has announced a change in the director’s interest, specifically for Bradley O’Connor, reflecting a shift in securities holdings. The change involved the sale of 338,429 ordinary shares and the exercise of 399,500 employee options, resulting in a new holding of 5,400,000 ordinary shares and 500,000 employee options. This adjustment in securities is part of the company’s ongoing management of its executive interests and could impact its market positioning and stakeholder perceptions.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Limited operates in the cognitive science industry, providing digital brain health assessments and services. The company focuses on developing and delivering cognitive tests and technology solutions for clinical trials, healthcare, and academic research.
YTD Price Performance: 136.21%
Average Trading Volume: 183,557
Technical Sentiment Signal: Buy
Current Market Cap: A$417.8M
For detailed information about CGS stock, go to TipRanks’ Stock Analysis page.